Posts Tagged ‘ Vioxx ’

Question: Which Transvaginal Mesh Trials are Next?

Feb 20th, 2013 | By
Question: Which Transvaginal Mesh Trials are Next?

MDND (Mesh Medical Device News Desk) and its FB Page have been receiving a lot of questions about which trials are scheduled to follow Linda Gross v. Ethicon, which on Thursday, February 28 resulted in an $11.1 million award to Linda and Jeff Gross. The award includes $7.76 million in punitive damages. See story here.
[continue reading...]



Lead Attorneys to be Chosen in Transvaginal Mesh Cases Friday, April 13

Apr 12th, 2012 | By
Lead Attorneys to be Chosen in Transvaginal Mesh Cases Friday, April 13

The Honorable Judge Joseph Goodwin will oversee a hearing Friday, April 13, to decide who will be the lead attorneys in the consolidated lawsuits over defective transvaginal mesh. Hundreds of cases have been consolidated in the Southern District of West Virginia in Multidistrict litigation (MDL) that name mesh manufacturers Ethicon, Inc ( MDL No. 2327),
[continue reading...]



Merck’s Blockbuster Vioxx Settlement

Nov 23rd, 2011 | By
Merck’s Blockbuster Vioxx Settlement

NOVEMBER 22, 2011-When a defective product has harmed so many people and cost so many lives, the settlement numbers are huge too. Now the U.S. Justice Department says it has settled its civil case with Merck, the pharmaceutical giant that aggressively marketed Vioxx (Rofecoxib) making it a blockbuster drug. Share this:



Is the FDA Killing Innovation? Fortune, September 2, 2011

Sep 3rd, 2011 | By

CNN reports on MelaFind, a handheld medical device that helps doctors spot melanoma using a noninvasive computer imaging.  But it is still not approved by the Food and Drug Administration, and may not be.  The agency refused to take the next step to approval in 2009, even though the machine was on the fast-track. Uncertainty
[continue reading...]



We hope you find this a helpful resource. National News Editor, Jane Akre, began MDND with the hope of providing the latest news, information and perspective from the regulatory, industry and patient point of view, something that goes under-reported in much of the coverage of medical devices. The public is just now becoming aware that many devices do not undergo the same scrutiny as prescription drugs and are instead grandfathered in under an FDA loophole that has gone largely unchanged since the 1970s. As a result, patients become the post-market clinical trial subjects, and many suffer devastating and permanent injuries.